Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
3.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
4.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
5.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639
6.
DIEER: Delay-Intolerant Energy-Efficient Routing with Sink Mobility in Underwater Wireless Sensor Networks.
Sensors (Basel)
; 20(12)2020 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575473
7.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
8.
A rare presentation of cephalad extension of an anterior mediastinal teratoma - A case report.
J Pak Med Assoc
; 69(6): 902-904, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31201402
9.
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Lancet Oncol
; 18(11): 1532-1542, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29033099
10.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 17(8): 1047-1060, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27339115
11.
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 16(16): 1605-16, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26522334
12.
Is there an antiandrogen withdrawal syndrome with enzalutamide?
BJU Int
; 115(3): 373-80, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24906049
13.
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
BJU Int
; 116(6): 880-7, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25639506
14.
Volumetric modulated arc therapy in prostate cancer patients with metallic hip prostheses in a UK centre.
Rep Pract Oncol Radiother
; 20(4): 273-7, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26109914
15.
Treatment of ingrown toe nail-comparison of phenolization after partial nail avulsion and partial nail avulsion alone.
J Ayub Med Coll Abbottabad
; 26(4): 522-5, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25672179
16.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Eur J Cancer
; 205: 114103, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729054
17.
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoecon Open
; 7(3): 345-358, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37084172
18.
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
Int J Radiat Oncol Biol Phys
; 113(2): 305-315, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35017008
19.
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PLoS One
; 17(6): e0269192, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653395
20.
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877084